LYKA LABS
|
The Current P/E Ratio of LYKA LABS is -116.93.
Share Price | ₹124.6 | Apr 29,2024 |
Market Cap | ₹412.4 Cr | |
Earnings-TTM | ₹-3.5 Cr | TTM-Consolidated Results |
Price/Earnings | -116.93x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of LYKA LABS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹412.4 Cr] as on Apr 29,2024
(/) Earnings [ ₹-3.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -116.93x ]
Thus, for LYKA LABS , the investors are currently willing to pay -116.93 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LYKA LABS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LYKA LABS over the last five years.
Historical PE (Price/Earnings) ratio chart of LYKA LABS
PE Ratio Performance Analysis for LYKA LABS
- LYKA LABS 's p/e ratio for fiscal years ending Mar2023 to Mar2019 averaged 2.00x.
- LYKA LABS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LYKA LABS 's p/e ratio peaked in Mar2022 at 9.98x.
- LYKA LABS 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does LYKA LABS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
LYKA LABS | -3.53 | -116.93 | 412.4 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 8,998.63 | 40.58 | 365,167.0 |
CIPLA LTD | 3,744.03 | 30.35 | 113,645.0 |
DR REDDYS LABORATORIES LTD | 5,209.40 | 20.15 | 104,987.0 |
ZYDUS LIFESCIENCES LTD | 2,954.20 | 32.82 | 96,950.6 |
DIVIS LABORATORIES LTD | 1,382.97 | 76.57 | 105,890.0 |
MANKIND PHARMA LTD | 1,743.30 | 54.78 | 95,492.3 |
TORRENT PHARMACEUTICALS LTD | 1,494.00 | 60.90 | 90,980.9 |
LUPIN LTD | 1,809.74 | 41.24 | 74,631.4 |
AUROBINDO PHARMA LTD | 2,777.89 | 24.29 | 67,488.4 |
ABBOTT INDIA LTD | 1,145.58 | 48.74 | 55,838.1 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LYKA LABS 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | -116.93x |
Max industry PE | 76.57x |
Median industry PE | 40.58x |
Average industry PE | 28.50x |
You may also like the below Video Courses